Since CD11c controls the neutrophil ROS generation and NETs formation, CD11c antagonist should be explored as a potential therapeutic for treating lupus, where NETs play a major role and the other nuclear antigens are released during NETs formation (118–120). Here, ITGAX is linked to systemic lupus erythematosus.